RECENT-TB Recurrent TB Screening and Prevention Study
- Coordinator
- Stichting Amsterdam Umc, Netherlands
- Runs
- 1 June 2026 to 31 May 2030
- Status
- Running
- EU funding
- €2.4m
- Total cost
- €2.4m
- Partners
- 4 organisations in 4 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101249004
What the project is doing
In the project's own words, from its summary on CORDIS.
Every year, 1.5 to 2 million people are successfully treated for tuberculosis (TB) in sub-Saharan Africa (SSA). Of these, on average 10% (150,000 to 200,000 people) experience recurrent TB disease within two years. The underlying mechanisms are a combination of relapse and reinfection, however the precise determinants are poorly understood. People with previous TB are missing in current TB guidelines and target product profiles.
However, this vulnerable population is disproportionately responsible for many reported TB episodes and is already captured within health systems. This represents a blind spot in TB control. Addressing this underserved population provides a huge opportunity to avoid recurrence and related healthcare costs. Recurrent TB can be prevented by secondary preventive TB therapy (sTPT), although data are limited. Through its integrated design, RECENT-TB will generate evidence on the clinical and cost-effectiveness of sTPT and its implementation context, on the predictive value of affordable screening tools and on the diagnostic performance of novel diagnostics to detect recurrent TB.
This evidence will allow development of a personalised risk score and cost-effective risk-stratified algorithms to target sTPT to those who will benefit the most, which will be translated into policy recommendations. RECENT-TB’s unique value proposition is that it will generate evidence to transform the management of recurrent TB in Africa through an innovative risk-stratification approach that will extend the use and improve the uptake of existing preventive, predictive and diagnostic interventions in this vulnerable and underserved population: people with previous TB.
The ambition of RECENT-TB is to halve the rate of TB recurrence and thereby avert 75,000-100,000 recurrences yearly in SSA, leading to reduced morbidity, mortality and further transmission.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Amsterdam Umc | Amsterdam | Netherlands | Coordinator |
| The Infectious Diseases Institute Limited | Kampala | UG | Participant |
| The University Court of the University of St Andrews | St Andrews | United Kingdom | Participant |
| Stellenbosch University | Stellenbosch | South Africa | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI